Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Gordon James Freeman, Ph.D.

Co-Author

This page shows the publications co-authored by Gordon Freeman and Kathleen Mahoney.
Connection Strength

4.408
  1. Acidity changes immunology: a new VISTA pathway. Nat Immunol. 2020 01; 21(1):13-16.
    View in: PubMed
    Score: 0.875
  2. A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer Immunol Immunother. 2019 Mar; 68(3):421-432.
    View in: PubMed
    Score: 0.814
  3. PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunol Res. 2015 Dec; 3(12):1308-15.
    View in: PubMed
    Score: 0.656
  4. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015 Aug; 14(8):561-84.
    View in: PubMed
    Score: 0.644
  5. Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses. Cancer Immunol Res. 2021 Oct 11.
    View in: PubMed
    Score: 0.247
  6. VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy. Trends Immunol. 2021 03; 42(3):209-227.
    View in: PubMed
    Score: 0.235
  7. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Cancer Immunol Res. 2021 02; 9(2):156-169.
    View in: PubMed
    Score: 0.233
  8. The importance of exosomal PDL1 in tumour immune evasion. Nat Rev Immunol. 2020 04; 20(4):209-215.
    View in: PubMed
    Score: 0.220
  9. Learning from PD-1 Resistance: New Combination Strategies. Trends Mol Med. 2016 06; 22(6):448-451.
    View in: PubMed
    Score: 0.170
  10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther. 2015 Apr 01; 37(4):764-82.
    View in: PubMed
    Score: 0.157
  11. Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. Haematologica. 2021 05 01; 106(5):1330-1342.
    View in: PubMed
    Score: 0.060
  12. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clin Cancer Res. 2019 04 01; 25(7):2174-2184.
    View in: PubMed
    Score: 0.051
  13. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res. 2017 06; 5(6):480-492.
    View in: PubMed
    Score: 0.046
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.